HC Wainwright & Co. Reiterates Neutral on Atara Biotherapeutics
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has reiterated a Neutral rating on Atara Biotherapeutics (NASDAQ:ATRA).
May 22, 2024 | 11:07 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. analyst Robert Burns has reiterated a Neutral rating on Atara Biotherapeutics. This suggests that the analyst does not foresee significant short-term changes in the stock's performance.
The reiteration of a Neutral rating indicates that the analyst does not expect significant positive or negative movement in the stock price in the short term. Investors may interpret this as a signal to hold their current positions.
CONFIDENCE 90
IMPORTANCE 50
RELEVANCE 100